This clinical trial is a non-interventional, observational, multicenter, post-marketing real-world study to evaluate the efficacy and safety of Inaticabtagene Autoleucel Injection in Chinese adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
The study is a non-interventional, observational, multicenter, post-marketing real-world study, and its objective is to evaluate the efficacy and safety of Inaticabtagene Autoleucel Injection in the treatment of Relapsed or Refractory acute lymphoblastic leukemia. The study consists of screening period including leukapheresis, treatment period, and follow-up period (2 years at most).
Study Type
OBSERVATIONAL
Enrollment
200
Peking University People's Hospital
Beijing, Beijing Municipality, China
RECRUITINGPeking University Third Hospital
Beijing, Beijing Municipality, China
RECRUITINGoverall survival
OS is defined as the time from the start date of Inaticabtagene Autoleucel Injection infusion to the date of death due to any cause.
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
RECRUITINGHenan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University
Zhengzhou, Henan, China
RECRUITINGUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
RECRUITINGThe Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
RECRUITINGQilu Hospital of Shandong university
Jinan, Shandong, China
RECRUITINGTongji Hospital of Tongji University
Shanghai, Shanghai Municipality, China
RECRUITINGWest China School of Medicine/West China Hospital of Sichuan University
Chengdu, Sichuan, China
RECRUITINGInstitute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China
RECRUITING